niacin and AIDS Seroconversion studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

Excerpt	Relevance	Reference
"A combination of fenofibrate and niacin with low-saturated-fat D/E is effective and safe in increasing HDL-C, decreasing non-HDL-C and hypertriglyceridemia, and ameliorating hypoadiponectinemia in patients with HIV/ART-associated dyslipidemia."	9.15	Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. ( Balasubramanyam, A; Ballantyne, CM; Clark, P; Coraza, I; Cuevas-Sanchez, E; Giordano, TP; Iyer, D; Kamble, S; Patel, P; Pownall, HJ; Scott, LW; Sekhar, RV; Smith, EO; Taylor, AA, 2011)
"A combination of fenofibrate and niacin with low-saturated-fat D/E is effective and safe in increasing HDL-C, decreasing non-HDL-C and hypertriglyceridemia, and ameliorating hypoadiponectinemia in patients with HIV/ART-associated dyslipidemia."	5.15	Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. ( Balasubramanyam, A; Ballantyne, CM; Clark, P; Coraza, I; Cuevas-Sanchez, E; Giordano, TP; Iyer, D; Kamble, S; Patel, P; Pownall, HJ; Scott, LW; Sekhar, RV; Smith, EO; Taylor, AA, 2011)

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

HDL-C

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Souza, SA	1
Chow, DC	1
Walsh, EJ	1
Ford, S	1
Shikuma, C	1
Balasubramanyam, A	1
Coraza, I	1
Smith, EO	1
Scott, LW	1
Patel, P	1
Iyer, D	1
Taylor, AA	1
Giordano, TP	1
Sekhar, RV	1
Clark, P	1
Cuevas-Sanchez, E	1
Kamble, S	1
Ballantyne, CM	1
Pownall, HJ	1
Nachamkin, I	1
MacGregor, RR	1
Staneck, JL	1
Tsang, AY	1
Denner, JC	1
Willner, M	1
Barbagallo, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376]		221 participants (Actual)	Interventional	2004-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Non-HDL-C

Intervention	mg/dl (Mean)
Group 1 - Usual Care	37.1
Group 2 - Diet/Exercise Only	38.7
Group 3 - Diet/Exercise + Fenofibrate	40.7
Group 4 - Diet/Exercise + Niacin	41.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin	44.8

non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Total Cholesterol

Intervention	mg/dl (Mean)
Group 1 - Usual Care	162.2
Group 2 - Diet/Exercise Only	165.4
Group 3 - Diet/Exercise + Fenofibrate	145.8
Group 4 - Diet/Exercise + Niacin	154
Group 5 - Diet/Exercise + Fenofibrate + Niacin	137.1

Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Total Cholesterol : HDL-C Ratio

Intervention	mg/dL (Mean)
Group 1 - Usual Care	195.6
Group 2 - Diet/Exercise Only	200.1
Group 3 - Diet/Exercise + Fenofibrate	184
Group 4 - Diet/Exercise + Niacin	190.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin	178.4

Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Triglycerides

Intervention	ratio (Mean)
Group 1 - Usual Care	5.2
Group 2 - Diet/Exercise Only	5.1
Group 3 - Diet/Exercise + Fenofibrate	4.5
Group 4 - Diet/Exercise + Niacin	4.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin	4

Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Body Composition

Intervention	mg/dL (Mean)
Group 1 - Usual Care	199
Group 2 - Diet/Exercise Only	216.9
Group 3 - Diet/Exercise + Fenofibrate	155.1
Group 4 - Diet/Exercise + Niacin	177.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin	135.6

"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks

Intervention	kg (Mean)
	Body cell mass	Fat mass
Group 1 - Usual Care	59.6	36.8
Group 2 - Diet/Exercise	67.3	37.5
Group 3 - Diet/Exercise + Fenofibrate	66.6	35.8
Group 4 - Diet/Exercise + Niacin	67.1	37.7
Group 5 - Diet/Exercise + Fenofibrate + Niacin	68.2	36.2

Intervention	micrograms/ml (Mean)
	Fasting insulin	HOMA-IR	Insulin sensitvity index	Adiponectin
Group 1 - Usual Care	8.7	1.92	3.54	7.12
Group 2 - Diet/Exercise Only	6.7	1.38	4.95	6.04
Group 3 - Diet/Exercise + Fenofibrate	9.5	2.02	3.81	5.24
Group 4 - Diet/Exercise + Niacin	11.9	2.76	2.88	11.01
Group 5 - Diet/Exercise + Fenofibrate + Niacin	10.3	2.38	2.38	10.34

Article	Year
Pilot study on the safety and tolerability of extended release niacin for HIV-infected patients with hypertriglyceridemia. Hawaii medical journal, 2010, Volume: 69, Issue:5 Topics: Adult; Delayed-Action Preparations; Glucose; HIV Seropositivity; Humans; Hypertriglyceridemia; Liver	2010
Niacin-positive Mycobacterium kansasii isolated from immunocompromised patients. Journal of clinical microbiology, 1992, Volume: 30, Issue:5 Topics: Adult; HIV Seropositivity; Humans; Immune Tolerance; Male; Middle Aged; Niacin; Nontuberculous Mycob	1992

niacin and AIDS Seroconversion